Sfoglia per AUTORE
BUSTREO S
Collezione AOU Città della Salute di Torino

  

Items : 11

Adverse events during first-line treatments for mCRC: The Toxicity over Time (ToxT) analysis of three randomised trials. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2023 Aug;189:112910. doi: 10.1016/j.ejca.2023.05.001. Epub 2023 May 6.
2023
AOU Città della Salute di Torino

Libertini M; Palermo F; Clavarezza M; Cupini S; Bustreo S; Procaccio L; Zaniboni A; Daniel F; Niger M; Tomasello G; Santini D; Morano F; Lonardi S; Carullo M; Raimondi A; Boccaccino A; Rossini D; Pietrantonio F; Cremolini C;

Response shift in health-related quality of life measures in the presence of formative indicators. in Health and quality of life outcomes / Health Qual Life Outcomes. 2021 Jan 6;19(1):9. doi: 10.1186/s12955-020-01663-y.
2021
AOU Città della Salute di Torino

Testa S; Di Cuonzo D; Ritorto G; Fanchini L; Bustreo S; Racca P; Rosato R;

Tailoring chemotherapy supply according to patients' preferences: a quantitative method in colorectal cancer care. in Current medical research and opinion / Curr Med Res Opin. 2020 Jan;36(1):73-81. doi: 10.1080/03007995.2019.1670475. Epub 2019 Oct 7.
2020
AOU Città della Salute di Torino

Racca P; Bustreo S; Fanchini L; Ritorto G; Rosato R; Di Cuonzo D; Pagano E;

The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials. in British journal of cancer / Br J Cancer. 2020 Aug;123(3):403-409. doi: 10.1038/s41416-020-0894-7. Epub 2020 May 19.
2020
AOU San Luigi di Orbassano
AOU Città della Salute di Torino

Tonini G; Adamo V; Loupakis F; Tomasello G; Zaniboni A; Murialdo R; Boccaccino A; Claravezza M; Bustreo S; Tampellini M; Borelli B; Sartore-Bianchi A; Rimassa L; Lonardi S; Marmorino F; Corallo S; Moretto R; Morano F; Antoniotti C; Guarini V; Fucà G; Cortesi E; de Braud F; Cremolini C; Pietrantonio F; Fucà G; Guarini V; Antoniotti C; Morano F; et alii...

2018
AOU Città della Salute di Torino

Di Nicolantonio F; Sartore-Bianchi A; Bardelli A; Esteller M; Siena S; Michels KB; Racca P; Grady WM; Truini M; Matullo G; Zavattari P; Vanzati A; Maden S; Bencardino K; Bustreo S; Cancelliere C; Guarrera S; Cristiano C; Oddo D; Binder AM; Falcomatà C; Mussolin B; Cassingena A; Ponzetti A; Moran S; Siravegna G; Barault L; Amatu A;

Ablation of colorectal liver metastasis: Interaction of ablation margins and RAS mutation profiling on local tumour progression-free survival. in European radiology / Eur Radiol. 2018 Jul;28(7):2727-2734. doi: 10.1007/s00330-017-5273-2. Epub 2018 Feb 7.
2018
AOU San Luigi di Orbassano
AOU Città della Salute di Torino

Vauthey JN; Odisio BC; Yevich SM; Sheth RA; Bustreo S; Fonio P; Veltri A; Gazzera C; Yamashita S; Calandri M; Calandri M; Yamashita S; Gazzera C; Fonio P; Veltri A; Bustreo S; Sheth RA; Yevich SM; Vauthey JN; Odisio BC;

Phase II Study of Preoperative Treatment with External Radiotherapy Plus Panitumumab in Low-Risk, Locally Advanced Rectal Cancer (RaP Study/STAR-03). in The oncologist / Oncologist. 2018 Aug;23(8):912-918. doi: 10.1634/theoncologist.2017-0484. Epub 2018 Mar 9.
2018
AOU Città della Salute di Torino

Damato A; Ciardiello F; Frassineti L; Bustreo S; Bergamo F; Marino A; Aschele C; Rosati G; Cordio S; Latiano T; Bochicchio A; Di Fabio F; Di Bisceglie M; Pinto C; Giaquinta S; Baldari D; Boni L; Pinto C; Di Bisceglie M; Di Fabio F; Bochicchio A; Latiano T; Cordio S; Rosati G; Aschele C; Marino A; Bergamo F; Bustreo S; Frassineti L; et alii...

FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2016 May;27(5):843-9. doi: 10.1093/annonc/mdw052. Epub 2016 Feb 9.
2016
AO Cuneo
AOU Città della Salute di Torino

Bustreo S; Ronzoni M; Buonadonna A; Bergamo F; Tomasello G; Tonini G; Allegrini G; Vitello S; Rossini D; Moretto R; Chiara S; Mancini ML; Granetto C; Lonardi S; Masi G; Loupakis F; Cremolini C; Barbara C; Boni L; Falcone A;

Optimal Ki67 cut-off for luminal breast cancer prognostic evaluation: a large case series study with a long-term follow-up. in Breast cancer research and treatment / Breast Cancer Res Treat. 2016 Jun;157(2):363-371. doi: 10.1007/s10549-016-3817-9. Epub 2016 May 7.
2016
AOU Città della Salute di Torino

Bustreo S; Osella-Abate S; Cassoni P; Donadio M; Airoldi M; Pedani F; Papotti M; Sapino A; Castellano I;

Dose to specific subregions of pelvic bone marrow defined with FDG-PET as a predictor of hematologic nadirs during concomitant chemoradiation in anal cancer patients. in Medical oncology (Northwood, London, England) / Med Oncol. 2016 Jul;33(7):72. doi: 10.1007/s12032-016-0789-x. Epub 2016 Jun 8.
2016
AOU Città della Salute di Torino

Franco P; Arcadipane F; Ragona R; Lesca A; Gallio E; Mistrangelo M; Cassoni P; Arena V; Bustreo S; Faletti R; Rondi N; Morino M; Ricardi U; Franco P; Arcadipane F; Ragona R; Lesca A; Gallio E; Mistrangelo M; Cassoni P; Arena V; Bustreo S; Faletti R; Rondi N; Morino M; Ricardi U;

Chimeric rat/human HER2 efficiently circumvents HER2 tolerance in cancer patients. in Clinical cancer research : an official journal of the American Association for Cancer Research / Clin Cancer Res. 2014 Jun 1;20(11):2910-21. doi: 10.1158/1078-0432.CCR-13-2663. Epub 2014 Mar 25.
2014
AOU Città della Salute di Torino

Occhipinti S; Sponton L; Rolla S; Caorsi C; Novarino A; Donadio M; Bustreo S; Satolli MA; Pecchioni C; Marchini C; Amici A; Cavallo F; Cappello P; Pierobon D; Novelli F; Giovarelli M;

©2026 Tutti i diritti riservati. Biblioteca Virtuale per la Salute - Piemonte